111 related articles for article (PubMed ID: 20048171)
41. Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm.
Pennathur A; Luketich JD; Landreneau RJ; Ward J; Christie NA; Gibson MK; Schuchert M; Cooper K; Land SR; Belani CP
Ann Thorac Surg; 2008 Jun; 85(6):1930-6; discussion 1936-7. PubMed ID: 18498797
[TBL] [Abstract][Full Text] [Related]
42. Spectrum of p53 mutations in biopsies from breast cancer patients selected for preoperative chemotherapy analysed by the functional yeast assay to predict therapeutic response.
Deissler H; Kafka A; Schuster E; Sauer G; Kreienberg R; Zeillinger R
Oncol Rep; 2004 Jun; 11(6):1281-6. PubMed ID: 15138567
[TBL] [Abstract][Full Text] [Related]
43. Neoadjuvant chemotherapy in head and neck cancer: should it be revisited?
Specenier PM; Vermorken JB
Cancer Lett; 2007 Oct; 256(2):166-77. PubMed ID: 17673364
[TBL] [Abstract][Full Text] [Related]
44. p53 tumor suppressor protein and H-RAS oncogene in maxillofacial tumors: immunohistochemical and genetic investigation, induction chemotherapy response and prognosis evaluation.
Cutilli T; Papola F; Di Emidio P; Corbacelli A
J Chemother; 1998 Oct; 10(5):411-7. PubMed ID: 9822361
[TBL] [Abstract][Full Text] [Related]
45. p53 overexpression and mutation, chemoresistance and patient survival in oral and maxillofacial squamous cell carcinoma.
Cutilli T; Papola F; Corbacelli A
J Chemother; 1997 Apr; 9(2):123-4. PubMed ID: 9176754
[No Abstract] [Full Text] [Related]
46. Correlation of p53 status with the response to chemotherapy-based treatment in esophageal cancer: a meta-analysis.
Zhang SS; Huang QY; Yang H; Xie X; Luo KJ; Wen J; Cai XL; Yang F; Hu Y; Fu JH
Ann Surg Oncol; 2013 Jul; 20(7):2419-27. PubMed ID: 23515910
[TBL] [Abstract][Full Text] [Related]
47. [Effectiveness of cisplatin with continuous infusion of 5-fluorouracil in neoadjuvant chemotherapy of carcinoma of the oral cavity].
Poruban D; Koza I; Mracna J; Nagy V; Vasko J
Bratisl Lek Listy; 1992 Aug; 93(8):395-400. PubMed ID: 1464019
[TBL] [Abstract][Full Text] [Related]
48. p53--master and commander.
Foulkes WD
N Engl J Med; 2007 Dec; 357(25):2539-41. PubMed ID: 18094374
[No Abstract] [Full Text] [Related]
49. p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series.
Cabelguenne A; Blons H; de Waziers I; Carnot F; Houllier AM; Soussi T; Brasnu D; Beaune P; Laccourreye O; Laurent-Puig P
J Clin Oncol; 2000 Apr; 18(7):1465-73. PubMed ID: 10735894
[TBL] [Abstract][Full Text] [Related]
50. Lactate dehydrogenase B is associated with the response to neoadjuvant chemotherapy in oral squamous cell carcinoma.
Sun W; Zhang X; Ding X; Li H; Geng M; Xie Z; Wu H; Huang M
PLoS One; 2015; 10(5):e0125976. PubMed ID: 25973606
[TBL] [Abstract][Full Text] [Related]
51. p53 expression in locally advanced pharyngeal squamous cell carcinoma.
Lassaletta L; Brandáriz JA; Benito A; de la Cruz J; Gómez C; Ballestín C; Hitt R; Colomer R; Alvarez-Vicent JJ
Arch Otolaryngol Head Neck Surg; 1999 Dec; 125(12):1356-9. PubMed ID: 10604414
[TBL] [Abstract][Full Text] [Related]
52. Neoadjuvant chemotherapy for advanced oral cavity cancer.
Yaniv D; Seiwert TY; Margalit DN; Williams MD; Barbon CEA; Largo RD; Smith JA; Gross ND
CA Cancer J Clin; 2024; 74(3):213-223. PubMed ID: 38329372
[No Abstract] [Full Text] [Related]
53. Histological effects and predictive biomarkers of TPP induction chemotherapy for oral carcinoma.
Hamakawa H; Bao Y; Takarada M; Tanioka H
J Oral Pathol Med; 1998 Feb; 27(2):87-94. PubMed ID: 9526736
[TBL] [Abstract][Full Text] [Related]
54. [Treatment of oral epidermoid carcinoma].
Reychler H
Rev Belge Med Dent (1984); 1999; 54(3):209-12. PubMed ID: 10898011
[TBL] [Abstract][Full Text] [Related]
55. Neoadjuvant chemotherapy: does it have benefits for the surgeon in the treatment of advanced squamous cell cancer of the oral cavity?
Olasz L; Szalma J; Orsi E; Tornóczky T; Markó T; Nyárády Z
Pathol Oncol Res; 2010 Jun; 16(2):207-12. PubMed ID: 19757193
[TBL] [Abstract][Full Text] [Related]
56. Preoperative Chemotherapy and Metronomic Scheduling of Chemotherapy in Locally Advanced Oral Cancers.
Patil VM; Noronha V; Joshi A; Banavali SD; Muddu V; Prabhash K
Oncology; 2016; 91 Suppl 1():35-40. PubMed ID: 27463093
[TBL] [Abstract][Full Text] [Related]
57. [No improvement in results after surgery, postoperative radiation therapy and neoadjuvant chemotherapy with TPF in locally advanced, resectable squamous cell carcinoma of the oral cavity ].
Klautke G
Strahlenther Onkol; 2013 Aug; 189(8):702-3. PubMed ID: 23771678
[No Abstract] [Full Text] [Related]
58. Predicting response to neoadjuvant therapy in esophageal cancer with p53 genotyping: a fortune-teller's crystal ball or a viable prognostic tool?
Nason KS
J Thorac Cardiovasc Surg; 2014 Nov; 148(5):2286-7. PubMed ID: 25444198
[No Abstract] [Full Text] [Related]
59. Necrosis of the tongue after arterial chemotherapy.
Shih CT; Hao SP; Ng SH; Yen KC
Otolaryngol Head Neck Surg; 1999 Nov; 121(5):655-7. PubMed ID: 10547491
[No Abstract] [Full Text] [Related]
60. Neoadjuvant versus induction chemotherapy: more than semantics.
Devisetty K; Wong SJ
J Clin Oncol; 2013 Aug; 31(23):2971-2. PubMed ID: 23733777
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
